Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.